文献速递艾滋病与性传播感染病毒性肝炎

HCV直接抗病毒药艾尔巴韦/格拉瑞韦与HIV整合酶抑制剂拉替拉韦、多替拉韦的药物相互作用评估

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

三项开放标签健康成人试验评估艾尔巴韦/格拉瑞韦与拉替拉韦或多替拉韦的药代动力学相互作用。结果显示联用无临床意义的药物相互作用,耐受性良好,支持HCV/HIV共感染者联用时无需调整剂量。

要点

  • 艾尔巴韦或格拉瑞韦与拉替拉韦或多替拉韦联用无临床显著相互作用。
  • 联用总体耐受性良好,支持HCV/HIV共感染人群无需调整剂量。
  • 多替拉韦与艾尔巴韦/格拉瑞韦联用时多替拉韦AUC略升高,但无临床意义。

核心结论

  • 艾尔巴韦或格拉瑞韦与拉替拉韦或多替拉韦联用未产生有临床意义的药物相互作用,且总体耐受性良好。
  • 结果支持HCV/HIV共感染者联用艾尔巴韦、格拉瑞韦、拉替拉韦或多替拉韦时无需调整剂量。

研究设计与样本

  • 三项开放标签试验在健康成年参与者中进行。
  • 拉替拉韦试验中,参与者接受单剂拉替拉韦400 mg、单剂艾尔巴韦50 mg或格拉瑞韦200 mg,以及拉替拉韦与艾尔巴韦或格拉瑞韦联用。
  • 多替拉韦试验中,参与者接受单剂多替拉韦50 mg单用或与每日一次艾尔巴韦50 mg和格拉瑞韦200 mg联用。

主要发现

  • 拉替拉韦AUC0-∞几何均值比(GMR)(90% CI)与艾尔巴韦联用时为1.02(0.81-1.27),与格拉瑞韦联用时为1.43(0.89-2.30)。
  • 多替拉韦AUC0-∞ GMR(90% CI)与艾尔巴韦和格拉瑞韦联用时为1.16(1.00-1.34)。
  • 艾尔巴韦AUC0-∞ GMR(90% CI)与拉替拉韦联用时为0.81(0.57-1.17),与多替拉韦联用时为0.98(0.93-1.04)。
  • 格拉瑞韦AUC0-24 GMR(90% CI)与拉替拉韦联用时为0.89(0.72-1.09),与多替拉韦联用时为0.81(0.67-0.97)。

临床怎么用

  • HCV/HIV共感染者联用艾尔巴韦/格拉瑞韦与拉替拉韦或多替拉韦时,无需调整任何药物剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elbasvir/grazoprevir is a once-daily fixed-dose combination therapy for the treatment of chronic HCV infection, including HCV/HIV coinfection. OBJECTIVES: To evaluate the pharmacokinetic interaction of elbasvir and grazoprevir with raltegravir or dolutegravir. METHODS: Three open-label trials in healthy adult participants were conducted. In the raltegravir trials, participants received a single dose of raltegravir 400 mg, a single dose of elbasvir 50 mg or grazoprevir 200 mg, and raltegravir with either elbasvir or grazoprevir. In the dolutegravir trial, participants received a single dose of dolutegravir 50 mg alone or co-administered with once-daily elbasvir 50 mg and grazoprevir 200 mg. RESULTS: The raltegravir AUC0-∞ geometric mean ratio (GMR) (90% CI) was 1.02 (0.81-1.27) with elbasvir and 1.43 (0.89-2.30) with grazoprevir. Dolutegravir AUC0-∞ GMR (90% CI) was 1.16 (1.00-1.34) with elbasvir and grazoprevir. The elbasvir AUC0-∞ GMR (90% CI) was 0.81 (0.57-1.17) with raltegravir and 0.98 (0.93-1.04) with dolutegravir. The grazoprevir AUC0-24 GMR (90% CI) was 0.89 (0.72-1.09) with raltegravir and 0.81 (0.67-0.97) with dolutegravir. CONCLUSIONS: Elbasvir or grazoprevir co-administered with raltegravir or dolutegravir resulted in no clinically meaningful drug-drug interactions and was generally well tolerated. These results support the assertion that no dose adjustments for elbasvir, grazoprevir, raltegravir or dolutegravir are needed for co-administration in HCV/HIV-coinfected people.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Feng HP, Guo Z, Ross LL, et al. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. J Antimicrob Chemother. 2019. PMID: 30541077. doi:10.1093/jac/dky465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。